Details
Stereochemistry | ACHIRAL |
Molecular Formula | C22H28N4O3.ClH |
Molecular Weight | 432.944 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCOC1=CC=C(CC2=NC3=CC(=CC=C3N2CCN(CC)CC)[N+]([O-])=O)C=C1
InChI
InChIKey=JTBRYBUIGVMMQL-UHFFFAOYSA-N
InChI=1S/C22H28N4O3.ClH/c1-4-24(5-2)13-14-25-21-12-9-18(26(27)28)16-20(21)23-22(25)15-17-7-10-19(11-8-17)29-6-3;/h7-12,16H,4-6,13-15H2,1-3H3;1H
Molecular Formula | C22H28N4O3 |
Molecular Weight | 396.4827 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Etonitazene is a potent and selective mu-opioid agonist. It was developed in CIBA. Administration of etonitazene may induce respiratory depression, and therefor etonitazene is not used in humans. Etonitazene is explicitly listed as an illegal drug under UN convention and is illegal throughout the world.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL233 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2167979 |
0.5 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2167979 |
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9537678
In rat tail-withdrawal assay, etonitazene was administered subcutaneously. ED50 was 0.38 mg/kg.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2167979
Binding of etonitazene to mu-opioid receptors from the membrane fraction of rat brains (minus cerebellum) was studied using [3H]DAMGO as a radioligand. Etonitazene binds to mu-opioid receptors with Ki of 0.5 nM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 02:09:38 GMT 2023
by
admin
on
Sat Dec 16 02:09:38 GMT 2023
|
Record UNII |
LD057W8P8B
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2053-25-0
Created by
admin on Sat Dec 16 02:09:38 GMT 2023 , Edited by admin on Sat Dec 16 02:09:38 GMT 2023
|
PRIMARY | |||
|
LD057W8P8B
Created by
admin on Sat Dec 16 02:09:38 GMT 2023 , Edited by admin on Sat Dec 16 02:09:38 GMT 2023
|
PRIMARY | |||
|
16334
Created by
admin on Sat Dec 16 02:09:38 GMT 2023 , Edited by admin on Sat Dec 16 02:09:38 GMT 2023
|
PRIMARY | |||
|
DTXSID50174523
Created by
admin on Sat Dec 16 02:09:38 GMT 2023 , Edited by admin on Sat Dec 16 02:09:38 GMT 2023
|
PRIMARY | |||
|
m5197
Created by
admin on Sat Dec 16 02:09:38 GMT 2023 , Edited by admin on Sat Dec 16 02:09:38 GMT 2023
|
PRIMARY | Merck Index |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|